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Abstract 
In 2013 both Saudi Arabia and Qatar launched genome projects with the aim of providing information for better diag-
nosis, treatment and prevention of diseases and, ultimately to realize personalized medicine by sequencing hundred 
thousands samples. These population based genome activities raise a series of relevant ethical, legal and social issues 
general, related to the specific population structure as well as to the Islamic perspective on genomic analysis and 
genetic testing. To contribute to the debate, the Authors after reviewing the existing literature and taking advantage 
of their professional experience in the field and in the geographic area, discuss and provide their opinions. In par-
ticular, the Authors focus on the impact of consanguinity on population structure and disease frequency in the Arab 
world, on genetic testing and genomic analysis (i.e. technical aspects, impact, etc.) and on their regulations. A com-
parison between the Islamic perspective and the ethical, social and legal issues raised in other population contexts 
is also carried. In conclusion, this opinion article with an up-to-date contribution to the discussion on the relevance 
and impact of genomic analysis and genetic testing in the Arab world, might help in producing specific national 
guidelines on genetic testing and genomic analysis and help accelerate the implementation and roll out of genome 
projects in Muslim countries and more specifically in Qatar, and other countries of the Gulf.
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Consanguinity, diseases and the Arab world
The history of Arabs extends more than 5000  years. 
Around 3500 BC, Semitic-speaking people of Arabian 
origin migrated into the valley of the Tigris and Euphra-
tes rivers in Mesopotamia, eventually becoming the 
Assyro-Babylonians. About 2500 BC, another group 
of Semites left the Arabian Peninsula and settled along 
the eastern shores of the Mediterranean; some of these 
migrants became the Amorites and Canaanites of later 
times. Starting 7th century, Arabs, proclaiming the new 
religion of Islam, ventured from the Arabian Peninsula 
and conquered the wide area from the Persian/Arabian 
Gulf to the Atlantic Ocean [1, 2]. Today, the geographic 
area of the Arab world covers about 14 million km2 and 
spans two continents covering a distance of 6375 km. In 
2004, the Arab population had an estimated size of more 
than 300 million people, contributing to 5  % of world 
populations, living in 22 countries across North Africa 
and West Asia, including the Middle East [1]. Residents 
share common demographic features, including a large 
family size, high rates of consanguinity, and rapid popula-
tion growth [2, 3].
Figure 1 shows that consanguinity is a prevailing tradi-
tion and is highly respected in most populations of North 
Africa, the Middle East and West Asia. First cousin 
unions are the most common, comprising 20–30 % of all 
marriages in given populations [4].
The rates and trends of first cousin marriages and 
other consanguineous marriages can vary hugely within 
and between populations and communities. Many 
factors determine these variances and they include 
ethnicity, religion, culture and geography. Emigrant com-
munities from highly consanguineous countries such as 
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Turkey, Pakistan and the Maghreb that are now resident 
in Europe, North America and Australia continue with 
the tradition of consanguineous marriages [4].
Consanguineous marriages are favored due to many 
sociocultural factors: the upholding of family groups and 
property, the better understanding of marital arrangements, 
the already established relationships with in-laws, and the 
monetary assets relating to dowry. Moreover, populations 
that favor consanguineous marriages believe that marry-
ing within one’s family reduces health and financial risks [5]. 
In the Middle East, consanguinity is not restricted to just 
the Muslim communities. Other Middle Eastern religious 
groups, including the Lebanese, Jordanian, and Palestinian 
Christian communities, also perpetrate the tradition of con-
sanguineous marriage, even though at a lesser rate than their 
Muslim counterparts and usually of lesser closeness [6–8].
Consanguineous marriages are highly regarded and 
are used to preserve wealth. They also present the ideal 
chance to maintain cultural stability and values [4, 5]. 
Consanguineous marriages are therefore believed to offer 
more stability for the married couple than marriages 
between non blood relatives. In most Arab societies, first 
cousin marriages are respected for many reasons. These 
marriages unite members of the same family as well as 
preserve the education of the offspring perpetrating the 
same family values. These views become even more sig-
nificant in times of social changes and political or socio-
economic insecurity [9, 10].
Consanguineous marriage becomes possible when 
there is available close kin of comparable age with simi-
lar socioeconomic standing as well as a traditional system 
that advocates for or against distinct types of consan-
guineous marriage [11]. In the past, distant consanguin-
ity was a rather familiar practice in rural communities. 
This custom eventually faded in Western societies as 
urbanization and industrialization in the nineteenth 
century increased. The two world wars of the twentieth 
century further contributed to the decline of consanguin-
eous marriage in Western societies [12].
In the Middle East, some regions have witnessed a 
decline in their consanguinity rates such as Jordan, Leba-
non and Palestine. Several factors could have contrib-
uted to this decline: a more educated female population, 
smaller families offering a decreased number of mar-
riageable close kin, growing urbanization and improved 
family finances. As the rates of infectious diseases 
decline, more attention is given to the health effects of 
consanguineous marriages. This increased public health 
awareness could have also contributed to the decline in 
consanguineous marriage rates [6–8].
Fig. 1 Global total consanguinity rates (extracted from [4])
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The decline in consanguineous marriage rates does not 
apply to all regions of the Middle East. Some Arab coun-
tries such as Qatar are seeing no significant reduction in 
their rates of consanguineous marriages. This could be 
attributed to the limited knowledge among the public 
regarding the nature of genetic risks that consanguineous 
marriages may present [4, 13, 14]. For these populations, 
the social benefits of close kin marriage outweigh any 
health risks. Society, culture, and politics still exercise a 
lot of influence in promoting intrafamilial marriages.
In populations where consanguinity and endogamy are 
practiced, the probability that a husband and wife are car-
riers (heterozygotes) for the same gene mutation that 
has been passed down to them from a common ances-
tor increases. Furthermore, this husband and wife couple 
will probably have many children. Consequently the odds 
that one or more of their children will inherit two copies 
of the ancestral recessive mutation, one from each parent, 
is increased [3, 5]. In populations with a high consanguin-
ity rate, one also expects a higher rate of recessive genetic 
disorders. This correlation, however, will be less noticeable 
in urban communities, as family size tends to be smaller [5, 
15, 16].
Some studies have shown a relationship between con-
sanguinity and some genetic conditions and health 
problems such as phenylketonuria (PKU) [17], immuno-
deficiency disorders [18], children’s hypertension [19], 
beta-thalassemia [20], protein-C and protein-S deficiency 
[21] and low birth weight [22]. Al Bu Ali et al. found that 
first cousins marriages represented the most significant 
risk factor for birth defects and inborn errors of metabo-
lism [23].
A few studies have reported a lack of effects of con-
sanguinity or even a mild protective effect on the risk of 
developing diseases like breast cancer. For example, Arab 
women whose parents are consanguineous displayed 
reduced breast cancer risk compared to those women 
whose parents are non-consanguineous [24, 25]. This 
might be due to that the long-term practice of consan-
guinity may decrease the frequency of deleterious gene or 
eliminate it from a population.
It has been observed that no association exists between 
consanguineous marriage and Down’s syndrome. Nev-
ertheless, it was noted that in some populations, the 
frequency of Down’s syndrome was elevated [26]. Zloto-
gora and Shaley observed that in an Arab village in Israel, 
cases of Down’s syndrome within the same endogamous 
group could not be explained by advanced maternal age 
alone [27].
The connection between consanguinity and major con-
genital malformations remains controversial [5]. It was 
shown that there was significantly increased risk of spe-
cific congenital heart defects in first cousin off-spring 
[28]. On the other hand, researchers conducted a 
genome-wide linkage analysis in South India, where 
uncle-niece and first cousin marriages are largely favored, 
and failed to determine a single gene of major effect in 
a clinically heterogeneous sample of consanguineous 
cases [29]. As regards to Qatar a survey published in 2010 
[10] has shown that a vast majority of the population did 
not know that consanguinity had been linked to serious 
genetic diseases or that distant cousin marriages were 
genetically less risky than unions between first cousins. 
Moreover, genetic data linked to consanguinity are avail-
able for hearing loss. In this case, despite the presence 
of clear inbreeding and different levels of consanguinity 
a quite significant amount of genetic heterogeneity was 
detected [30].
Final statement
The issue of consanguinity in Qatar and the Gulf region 
attracts much public attention. In many cases this issue 
is viewed negatively as a problem for both the family and 
the country. However, recent data clearly confirms that 
consanguinity has a minor impact on increasing disease 
frequency. Attention should be paid to:
1. Improving education about the health effects of con-
sanguinity to help avoid feelings of guilt among the 
consanguineous populations.
2. Educating the physicians on the importance of focus-
ing on some specific diseases whose frequency might 
be increased due to consanguinity, for example: 
thalassemia, hearing loss, intellectual disability, etc.
3. Offering premarital genetic screening for the most 
common population specific genetic diseases.
Genetic testing: general principia and the Islamic 
perspective
The term “genetic testing” refers to a series of techniques 
including molecular analysis of human nucleic acids 
(DNA and RNA). Genetic tests are used as a health care 
tool to detect gene variants associated with a specific dis-
ease or condition and for studying complex and quantita-
tive traits such cardiovascular diseases, cancer, diabetes, 
etc. Other fields include (a) pharmacogenetics where 
genetic tests are used to predict the effectiveness of ther-
apeutics and guide their administration, (b) nutrigenetics 
and lifestyle where tests are used to asses diet response, 
lifestyle habits, physical activity predisposition, etc. (c) 
and other non-clinical uses (paternity testing, forensics, 
cosmetics, etc.).
Prenatal genetic tests are carried out on pregnant 
women to detect abnormalities/mutations in the fetus. 
Post-natal genetic tests are carried out after birth. More-
over, depending on their ultimate purpose, genetic tests 
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can be divided into the following categories: (1) diag-
nostic, used to determine if the person is affected by a 
genetic disorder, (2) presymptomatic and predictive, 
when there is a family history of a genetic condition, 
undergoing genetic testing before symptoms actually 
appear may show if the person is at risk of developing 
that condition, (3) carrier testing, to detect the carrier 
status for recessive genetic diseases, such as thalassemia 
or cystic fibrosis, or if someone belongs to an ethnic 
group that has a high risk of a particular genetic disor-
der (e.g. Tay–Sachs disease in Jewish populations). The 
identification of a carrier status has relevant reproductive 
implications, (4) newborn screening, aimed at screening 
for certain genetic abnormalities that cause specific con-
ditions such as PKU. In such cases, care and treatment 
can begin immediately following positive test results, (5) 
preimplantation testing, aimed, during an in vitro fertili-
zation process, at diagnosing embryos for genetic defects 
in order to implant only those without them.
Depending on the type of test to be carried out differ-
ent sources of DNA can be used, such as blood samples, 
cheek and buccal swabs, saliva, amniotic fluid cells, cho-
rionic villus sampling, fetal cord blood cells, etc.
At the very early beginning, genetic tests were only 
available to detect chromosomal abnormalities (also 
called karyotyping). Then, with the development of the 
“Southern Protocol”, genetic testing also became available 
to investigate genes causing rare and inherited disorders 
like thalassemia or sickle cell anemia. The availability of 
PCR protocols led to a spread of tests that are able to 
detect even single point mutations in a very large number 
of genes underlying many inherited diseases.
Nevertheless, the positive detection rate of genetic 
testing varies largely from 10 to 80 % or more depending 
on several different limiting factors: clinical and genetic 
heterogeneity, accuracy and sensitivity of the technology 
used, etc. More recently, thanks to a series of technologi-
cal improvements and new high-throughput protocols, 
the variety of genetic tests has greatly increased to also 
include multiple genes tests [31]. As a matter of fact, 
the use of Massively parallel sequencing (MPS) tech-
nologies and in particular of targeted-resequencing 
(TRS) has allowed to assess multiple genetic causes for 
many genetic diseases such as Fanconi anemia, Usher 
syndrome, retinopathy, hearing loss, cancer, ataxias, 
cardiomyopathies, etc. Moreover, the use of other high-
throughput technologies such as SNPs arrays enables to 
detect small size insertions or deletions of genetic mate-
rial (molecular karyotyping) as well as run of homozy-
gosity. Molecular karyotyping is now considered as a 
first-line diagnostic test in comparison to traditional kar-
yotype analysis in several areas of postnatal chromosome 
analysis.
Once a genetic test is carried out, the information 
should be accurately transmitted and explained to the 
patient and professional experts. Genetic test results may 
present various different situations, detailed below.
The identification of a genetic cause, in other words, 
a positive diagnostic genetic test, will help physicians 
determine the right treatment (i.e. genotype–pheno-
type correlations) as well as develop a management plan 
which will allow relatives to receive accurate risk assess-
ments from a genetic counselor. The genetic counsellor 
might help the couple in making more informed family 
planning decisions. In the case of predictive tests where 
a positive test does not necessarily mean that someone 
will get that disorder, it would be possible to make life-
style changes that may decrease the risk of developing a 
disease or decrease its impact.
A negative result means that a genetic alteration was 
not detected by the test. The absence of results can be 
explained by (1) the accuracy and sensitivity of the test 
which does not fully guarantee a positive outcome, and 
(2) the presence of large genetic heterogeneity hamper-
ing the mutation detection. Of course, if someone does 
not have the genetic alteration, this finding does not 
necessarily mean he or she will never get the disease. 
Moreover, in some cases, a genetic test may not be able 
to provide helpful information for the presence of DNA 
variants whose pathogenic role is doubtful. The use of 
TRS (and more broadly MPS) increases the possibility 
to detect such “doubtful” variants leading to increased 
uncertainty instead of clear-cut results. In these situa-
tions, follow-up testing may be necessary and such vari-
ants might be reinterpreted over time, as we learn more 
and potentially develop functional assays. This finding 
raises the question of whether there is a legal or moral 
responsibility to report such variants and eventually to 
recall, in the future, patients and their relatives and if so, 
with whom does the responsibility lie?
In many societies subjects deal with the cultural fear of 
being associated with a genetic disease and the following 
possible stigmatization within the community. This find-
ing might lead to social disadvantages such as (a) mar-
riage refusal if subjects belong to families with a known 
genetic disease and (b) consideration of another marriage 
in presence of affected fetuses or children. All family 
members are affected by the negative connotations asso-
ciated with the presence of a genetic disease especially 
female family members. In the absence of major and 
effective therapeutical protocols for inherited diseases, 
genetic testing can help in making earlier and presymp-
tomatic diagnosis as well as preventing a genetic dis-
ease through a selective termination of an affected fetus, 
which, of course, raises continuous ethical debates in all 
societies including the Islamic ones. The Islamic schools 
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of thought have agreed that abortion is possible and law-
ful if continuation of the pregnancy will endanger a moth-
er’s life [32, 33]. Moreover, the Islamic Jurisprudence 
Council of the Islamic World League released in 1990 a 
religious advise (fatwa) allowing abortion in the presence 
of severe fetal malformations not amenable to treatment 
or leading to poor quality of life of patients and their rela-
tives [34, 35]. Abortion should be carried out prior to 
ensoulment thus, as largely agreed upon in the Islamic 
world, is before 120 days post fertilization. Interestingly, 
Islamic religious rules can be used by Muslims worldwide 
as they are not restricted to the country where subjects 
were born or are resident [33]. Within this framework 
and despite the absence of established networks of refer-
ral centers for genetic testing and counseling in the Arab 
world, a series of pilot studies and experiences has been 
reported in all fields of genetic testing over the past dec-
ade. This has been made possible, thanks to the presence 
of certain research centers, international collaborations, 
and the increase in the availability of advanced DNA 
technologies for the molecular analysis. As regards to 
diagnostic tests for genetic diseases there is a quite long 
standing experience in providing molecular diagnosis for 
some common inherited diseases such as thalassemia, 
sickle cell anemia, cystic fibrosis, hearing loss, etc. As 
regards complex traits, recently, a large survey on Saudi 
women has demonstrated high interest in genetic test-
ing for breast cancer [36]. An even larger experience 
has been obtained on prenatal diagnosis (PND), preim-
plantation diagnosis (PGD) and premarital screening 
for inherited disease. As regards PGD it resulted that 
this option is, in principle, acceptable in Saudi Arabia 
and might be considered for a range of different condi-
tions [37, 38] with an accurate selection of couples that 
should be counseled appropriately. Interestingly, 86 % of 
couples that already have experienced thalassemia (i.e. 
one affected child) expressed interest in PGD and were 
well aware about the possible benefits of this technology 
to avoid another affected child [39]. Usually, also PND 
is widely accepted even if data are mainly available on 
thalassemia, one of the most frequent inherited diseases 
in these populations. Interesting examples on a very good 
PND acceptability have been reported for thalassemia 
in West Bank and Gaza, where all couples with affected 
fetuses opted for abortion [40], always for thalassemia in 
Saudi Arabia [34], and for monogenic disorders in Israeli 
Arabs [27]. Finally, as regards to premarital screening for 
carrier identification, usually a positive attitude towards 
this approach has been reported in Saudi Arabia for 
hemoglobinopathies [41], in Syria among university stu-
dents [42], in Iran [43] and in Dubai [44]. Since the end 
of 2009, Qatar has started mandatory premarital genetic 
screening to fight against the population’s most prevalent 
genetic diseases, such as homocystinuria, cystic fibrosis 
and spinal muscular atrophy, with further optional tests 
for beta-thalassemia, sickle cell anemia, fragile-X among 
others. Currently, genetic tests for 27 most prevalent 
genetic diseases of Qatari population are provided by the 
Molecular Genetics Laboratory and genetic counselling 
is offered by the Clinical Genetics Department of Hamad 
Medical Corporation. Additional rarer tests are carried 
out by private companies.
Final statements
1. Genetic risks should be accurately explained dur-
ing pre- and post-genetic test counseling, preventive 
options including PND should also be presented and 
discussed and a formal discussion about termination 
of pregnancy and the Islamic fatwa should take place.
2. Improved educational plans should be developed 
to help improve the understanding of genetics and 
genetic-related diseases among the general popula-
tion as well as the physicians.
3. Where applicable networks of referral centers for 
genetic testing should be established or better 
improved to take care of the large number of genetic 
diseases present in the region.
Genetic testing in the new era (genomic analysis)
Since the completion of the sequencing of the human 
genome, the demand for genetic analysis in the human 
health care system has increased, and molecular genetic 
diagnostics are urgently needed. However, many genetic 
diseases are molecularly and clinically heterogeneous, 
and until recently, the available techniques lacked the 
necessary ability to analyze several genes in parallel. The 
recently introduced MPS technology of next-generation 
sequencing now offers the unique opportunity to extend 
molecular genetic analysis by introducing this high-
throughput technique, and by developing tailor-made 
medical re-sequencing approaches for gene identification 
and for the diagnosis of heterogeneous disorders. Whole 
genome sequencing (WGS) allows for the identification 
of all the possible variants at once, including chromo-
somal copy number variants. Protein-coding genes make 
up 1 % of the human genome but contain about 85 % of 
disease-causing mutations [45]. Therefore, efficient strat-
egies for selectively sequencing all coding regions of the 
genome (i.e. ‘‘Whole Exome Sequencing” or “WES’’) or a 
panel of genes (i.e. “Targeted Re-Sequencing” or “TRS”) 
have the potential to contribute to the understanding 
of rare and common human diseases [45, 46]. Recent 
data demonstrate the ability to capture more than 95 % 
of the targeted coding sequences with high sensitiv-
ity and specificity for the detection of both homozygous 
and heterozygous alleles. For dominant traits, we expect 
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that many, whose causes have not yet been identified, 
will be explained by alleles that have been difficult to 
map by linkage analysis due to the lack of availability of 
large families. Possible explanations are: reduced pen-
etrance, the presence of substantial locus heterogeneity, 
the presence of alleles that impair reproductive fitness 
to the extent that many affected subjects harbor de novo 
mutations. The finding of independent de novo muta-
tions within the same gene among different unrelated 
cases would constitute compelling evidence of disease 
causation. Moreover, in the presence of locus heteroge-
neity, identification of a significant excess in the num-
ber of independent mutations in the same gene, versus 
that expected by chance, will constitute evidence that a 
disease gene has been identified. Mapping data, which 
defines the location of the disease locus, animal models 
that produce similar phenotypes, and compelling func-
tional biology assays can all contribute to the identifica-
tion of such loci. For recessive traits, affected subjects 
arising from consanguineous unions contain substantial 
mapping information (i.e. the disease locus is expected to 
be homozygous). Such evidence reduces the region that 
must be analyzed by bioinformatics analysis upon MPS. 
The clinical utility of WES is well documented and has 
implications for disease gene discovery and clinical diag-
nosis [47]. Moreover, given the current rate of scientific 
advancement in genomics, MPS costs will continue to 
decrease making this technology accessible to an ever 
widening audience. In this light, MPS will be also used to 
study and diagnose quantitative and complex traits, for 
screening purposes, as well as to simply satisfy people’s 
curiosity about what their genome can tell about them 
[48, 49] (http://www.personalgenomes.org).
However, all these technological and diagnostic 
achievements have not yet led to updated and compre-
hensive guidelines and algorithms for the genetic diag-
nosis of many genetic diseases, which may be easily 
accessed by all the stakeholders involved: patients, clini-
cians, and geneticists. For example, since the publication 
of the “Genetic evaluation guidelines for the etiologic 
diagnosis of congenital hearing loss” by the American 
College of Medical Genetics [49], only sparse guidelines 
have been described in relation to multi-gene screen-
ing approaches, some of them issued by hospital labo-
ratories (http://www.cincinnatichildrens.org/service/g/
genetic-hearing-loss/default/).
As to Qatar, the recent launch of the Qatar Genome 
Project will “chart a road map for future treatment 
through personalized medicine” in the country. The 
ambitious goal of providing each citizen with his/her own 
genome, will lead to the discovery of almost all disease 
genes affecting the Qatari population, as well as a bet-
ter understanding of the interaction between genes and 
the environment. These findings will translate into more 
accurate and personalized treatments as well as preven-
tive plans and new lifestyle indications. Moreover, this 
project will pioneer the use of new genomic tools in con-
sanguineous populations hopefully showing the great 
potential that these new tools have to reshape healthcare 
delivery in Qatar, and in a more broad sense, in other 
regional countries and inbred populations.
Finally, beyond the rapidly evolving technical aspects, 
several key ethical issues arise in the clinical translation 
of MPS. In particular, the following issues should be 
taken into account:(a) Return of results, and in particular 
disclosure of ‘incidental findings’ (if such a term may still 
be used to refer to something we are searching for: (a) 
Green RC & Genomics [50]; (b) structuring the informed 
consent process and allowing decisions related to the 
return of results. Moreover, consents should be deeply 
focused on the relevance of privacy (see genomic privacy 
below), (c) special situations with relatives and children, 
including ‘duty to warn’ at risk relatives and family com-
munication issues including the role of consanguinity 
and (d) genomic privacy. Genomes not only uniquely and 
irrevocably identify their owner but also will have privacy 
repercussions for any relatives because they potentially 
reveal half of the genome of the parents and children and 
a substantial fraction of that of siblings Despite the fact 
that we are living in a world characterized by an impres-
sive erosion of individual privacy (web pages and social 
networks that disclose any kind of personal information, 
the possibility of confidential emails being widely circu-
lated, etc.) it should be clear that genome analysis under-
cuts privacy to a new degree.
Final statements
1. The use of MPS technologies (i.e. WGS, WES and 
TRS) to answer specific clinical testing indications 
might lead, under some specific circumstances, to 
results beyond the scope of the test itself (called ‘inci-
dental’ or ‘secondary’ findings). Thus, stakeholders 
must agree and determine which findings should be 
disclosed, when and in what manner. A good exam-
ple is the list of recommendations published in 2013 
by the American College of Medical Genetics and 
Genomics. They include a series of conditions and 
genes that should be considered, on the basis of clini-
cal outcome and therapeutical options, ‘mandatory’ 
to return.
2. The presence of variants with uncertain functional 
role raises a series of open questions. Have the sub-
jects/patients the ‘right’ to receive all of their genetic 
information or should they only be informed of data 
that are currently considered clinically relevant data? 
In any case, what about reinterpretation? Who is 
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going to provide it and when, how to further report 
the results, etc.? Again stakeholders should agree in 
advance on what actions to take.
3. So far, classical and standard models of informed 
consent for genetic testing have been widely used. 
They are mainly administered through a genetic 
counseling session carried out by clinical geneticists 
and/or genetic counselors. During the counseling, 
testing options, risks, benefits and limitations of 
genetic testing are discussed in detail. This approach 
is not feasible with MPS data because of the large 
amount of genomic information that is generated by 
MPS technologies. If we are to uphold the necessity 
to discuss thoroughly all the information obtained, 
then the process will be long and tiresome. One 
way of resolving this problem is to create very well 
trained and multidisciplinary teams which would 
include geneticists, physicians and bioinformaticians 
amongst others. In all cases, the consent form should 
be prepared accordingly and must reflect this broad 
and complex situation. Alternatively, an individual 
undergoing MPS may be requested to complete a 
short online course explaining the advantages and 
disadvantages of this technology.
4. Reiterating earlier discussion, genomic analysis may 
generate a wealth of new genetic information with 
clinical relevance. Some of this genetic data may also 
impact the patient’s relatives. For example, MPS data 
may identify a predictive risk factor for cardiovascu-
lar disease without any relevance to the patient: the 
patient’s biochemical and clinical parameters are 
normal, the patient leads a healthy lifestyle, etc. How-
ever, this data may be of possible value to other rela-
tives who might have completely different lifestyle 
habits and additional genetic and or environmental 
risk factors. This finding is even more relevant in 
inbred populations such as the Qatari population 
where kinship is very high and genetic results from 
one individual can be used, at least in part, to draw 
conclusions related to his/her relatives.
5. Huge efforts should be made related to informing 
and educating the public as to the great potential 
benefits arising from data, but also on the possible 
negative repercussions for the individual and his/her 
family should the data be casually and widely shared.
6. Most likely, in the near future, genomic analysis will 
oblige the society to reevaluate the current stand-
ards of medical confidentiality and privacy, a situa-
tion similar to the extensive use of internet and how 
that has changed our perceptions of personal space 
and privacy. Henceforth, substantial resources should 
be allocated to rapidly develop appropriate policies, 
guidelines and rules.
Regulations and legislations of genetic testing 
worldwide including the Arab world
In the USA, three different federal agencies play a role 
in the regulation of genetic tests: Centers for Medicare 
and Medicaid Services (CMS), Food and Drug Admin-
istration (FDA), and the Federal Trade Commission 
(FTC). The CMS is responsible for regulating all clinical 
laboratories performing genetic testing, ensuring their 
compliance with the Clinical Laboratory Improvement 
Amendments of 1988. The FDA has the largest author-
ity in terms of regulating the safety and effectiveness of 
genetic tests. Finally, the FTC aims at regulating genetic 
test advertising to ensure that it is not false or mislead-
ing. Regulations on genetic testing were and are still 
provided by a series of reports and acts such as: (1) NIH-
Department of energy task force on genetic testing rec-
ommendation in 1997; (2) secretary’s advisory committee 
on genetic testing report in 2000; (3) secretary’s advi-
sory committee on genetics, health and society report 
in 2008; (4) the laboratory test improvement act in 2006; 
(5) genomics and personalized medicine act in 2007; (6) 
genetic information nondiscrimination act in 2008; (7) 
framework for regulatory oversight of laboratory devel-
oped test (LDTs) in 2014; (8) FDA notification and medi-
cal device reporting for LDTs always in 2014.
In the EU there is a lack of specific genetic legislation. 
Nevertheless, some general principles are clearly defined: 
genetic data pertaining to health is ‘sensitive data’ under 
the EU data protection directive, and is thus to be treated 
confidentially. Likewise, discrimination based on genetic 
features is prohibited in the EU member states. Despite 
this legislative deficiency at EU level, several national leg-
islations have been approved so far. The first explicit law 
including genetic testing was enacted in France in 1994 
(Loi 94–653 and 94–654, later revised in 2004 and 2011). 
Soon after, specific legislations have been approved in 
Norway, Spain, Italy, Germany, Austria, Portugal, Sweden 
and Switzerland. In any case, most countries have appli-
cable provisions for genetic testing in the general legal 
framework governing other medical, laboratory and pro-
fessional activities in biomedicine, and other legislation, 
such as in  vitro fertilization and PGD, data protection, 
patient rights, and discrimination.
In Australia the provision of pathology services is 
regulated by the department of health and aging admin-
istration of the funding schemes for public health is by 
Medicare. Under the provisions of the health insur-
ance act 1973 (Cth) (HI Act), only accredited labora-
tories are eligible for Medicare benefits for only those 
tests or services listed on the Medicare benefits sched-
ule. Accreditation of testing services is administered by 
the national association of testing authorities (NATA), 
the only national accreditation body endorsed by the 
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Commonwealth government to assess laboratory com-
petency. The accreditation scheme is based on guidelines 
issued by the national pathology accreditation advi-
sory council (NPAAC). Before providing a genetic test 
through the Medicare benefits it should be assessed in 
compliance with the NPAAC guidelines. Genetic testing 
services generally comply with, but are not legally bound 
to the ethical aspects of human genetic testing informa-
tion paper and guidelines on genetic research released 
by the national health and medication research council 
(NHMRC).
China’s regulatory position on genetic tests was quite 
unclear until March 2014 when the China food and drug 
administration (CFDA) acted to impose regulatory con-
straints on medical institutions (and other providers) 
related to the provision of clinical genetic tests. As a first 
measure CFDA issued a ban on all medical applications 
of ‘gene sequencing technology products’ such as disease 
prevention (including prenatal diagnosis) and diagnosis, 
treatment and monitoring, health status assessment and 
genetic risk factor prediction. It applies to manufacture, 
import, sale or use (including software) of MPS technol-
ogy and genetic testing.
According to a quite recent survey from UNESCO 
(UNESCO Cairo Office, 2011), only Lebanon has written 
a law specifically formulated to regulate genetic testing 
(No. 625 of 2004). For all the remaining Arab countries, 
the issue of the regulation of genetic testing has been 
only partially addressed. In particular, many Arab coun-
tries, Bahrain, Tunisia, UAE, Saudi Arabia, Palestine, 
Oman, Kuwait, Algeria, Egypt and Jordan, have referred 
to genetic testing in relation to other procedures such 
as premarital screening, reproductive medicine, foren-
sic medicine, biobanking, etc. or directly to worldwide 
accepted international guidelines and regulations. In 
some other cases, such as Syria and Morocco several 
laboratories perform genetic testing despite the absence 
of specific legislation. As regards to Qatar, quite recently 
the Shafallah Genetics Medical Centre has produced 
a formal operation manual that includes guidelines on 
genetic testing and release of information, stating that 
genetic data should not be given to insurance companies, 
employers, schools, or governments, except after obtain-
ing the full informed consent of the person tested. Prena-
tal diagnosis should be offered to those who need it, but 
without applying any pressure on parents to agree to such 
testing. Strong attention should be paid in providing pro-
tection to minors and disabled persons. Genetic counsel-
ling should be given in a compassionate and professional 
manner, offering guidance and allowing individuals and 
families to make an informed choice.
Till present, the Department of Biomedical Research 
of the Supreme Council of Health in Qatar has prepared 
several policies and guidelines related to genetic testing, 
however, these guidelines are only present in a specific 
policy on diabetes mellitus.
A summary of the web links for some of the above 
mentioned agencies is given in Table 1.
Final statements
1. The absence of clearly defined policies and regula-
tions related to “sensitive data”, discrimination, data 
protection, and privacy in Qatar means that each 
genetic test provider center must develop its own 
policies based on international regulations governing 
this type of testing. In that effect, this current draft 
may be used as a helpful review.
2. Qatari academic and research centers together with 
the other major players in Qatar, should collaborate 
to work on producing specific national guidelines on 
genetic testing and genomic analysis to be approved 
and released by the department of biomedical 
research in the supreme council of health. This legal 
framework will help accelerate the implementation 
and roll out of the Qatar genome project.
Table 1 Links of  a series of  regulatory agencies/commissions involved in  regulations of  genetic testing in  different 
countries
Centers for Medicare and Medicaid services (CMS) https://www.cms.gov/ USA
Food and Drug Administration (FDA) http://www.fda.gov/ USA
Federal Trade Commission (FTC) https://www.ftc.gov/ USA
Department of Health http://www.health.gov.au/ Australia
NATA http://www.nata.com.au/nata/ Australia
National Pathology Accreditation Advisory Council (NPAAC) http://www.health.gov.au/npaac Australia
National Health and Medication Research Council (NHMRC) https://www.nhmrc.gov.au/ Australia
CFDA http://eng.cfda.gov.cn/WS03/CL0755/ China
SCH http://www.sch.gov.qa/home-en Qatar
European Commission http://ec.europa.eu/ Europe
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Conclusion
This opinion article provides an up-to-date contribution 
to the discussion on the relevance and impact of increas-
ing knowledge on genomic analysis and genetic testing in 
the Arab world. This new data can potentially form a new 
resource from which scientists and physicians can bring 
fresh insights to the world genomics community with 
a strong impact on understanding the genetic bases of 
mendelian as well as complex diseases (i.e. cardiovascu-
lar diseases, diabetes, metabolic syndrome, etc.). In this 
light, this paper might help in producing specific national 
guidelines on genetic testing and genomic analysis and 
further help accelerating the implementation and roll out 
of genome projects in Muslim countries and more spe-
cifically in Qatar, and other Arab countries of the Gulf.
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